Q1 EPS Estimate for Pacira BioSciences Reduced by Analyst

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Analysts at Zacks Research reduced their Q1 2026 earnings per share estimates for Pacira BioSciences in a report released on Tuesday, October 15th. Zacks Research analyst R. Department now expects that the company will earn $0.73 per share for the quarter, down from their prior forecast of $0.81. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.24 per share. Zacks Research also issued estimates for Pacira BioSciences' Q2 2026 earnings at $0.77 EPS, Q3 2026 earnings at $0.84 EPS and FY2026 earnings at $3.37 EPS.

A number of other equities analysts also recently weighed in on the stock. Royal Bank of Canada lifted their target price on shares of Pacira BioSciences from $14.00 to $15.00 and gave the stock a "sector perform" rating in a research note on Friday, October 4th. Barclays downgraded Pacira BioSciences from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $38.00 to $25.00 in a research note on Wednesday, July 3rd. Needham & Company LLC cut their target price on Pacira BioSciences from $43.00 to $22.00 and set a "buy" rating on the stock in a research report on Monday, August 12th. StockNews.com downgraded Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a report on Monday, August 12th. Finally, JPMorgan Chase & Co. reissued an "underweight" rating and issued a $10.00 price target (down from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Pacira BioSciences has a consensus rating of "Hold" and a consensus target price of $24.20.

Pacira BioSciences Trading Up 1.9 %

Pacira BioSciences stock traded up $0.32 during mid-day trading on Thursday, hitting $16.95. 531,136 shares of the stock were exchanged, compared to its average volume of 889,525. The firm's fifty day simple moving average is $14.64 and its two-hundred day simple moving average is $22.20. The company has a quick ratio of 5.70, a current ratio of 6.82 and a debt-to-equity ratio of 0.67. Pacira BioSciences has a 12 month low of $11.16 and a 12 month high of $35.95. The stock has a market capitalization of $788.95 million, a price-to-earnings ratio of 11.94 and a beta of 0.84.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.11. The company had revenue of $178.02 million during the quarter, compared to analysts' expectations of $173.31 million. Pacira BioSciences had a return on equity of 13.22% and a net margin of 9.21%.

Insider Activity at Pacira BioSciences

In related news, CEO Frank D. Lee acquired 8,264 shares of the stock in a transaction dated Monday, August 12th. The stock was purchased at an average cost of $12.10 per share, with a total value of $99,994.40. Following the completion of the purchase, the chief executive officer now directly owns 107,784 shares in the company, valued at $1,304,186.40. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have acquired 11,176 shares of company stock valued at $136,240. 6.40% of the stock is owned by corporate insiders.

Institutional Trading of Pacira BioSciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC grew its position in Pacira BioSciences by 229.6% in the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock worth $38,000 after purchasing an additional 932 shares in the last quarter. Park Place Capital Corp purchased a new position in Pacira BioSciences in the second quarter worth $46,000. Innealta Capital LLC purchased a new stake in shares of Pacira BioSciences during the 2nd quarter valued at $50,000. nVerses Capital LLC raised its stake in shares of Pacira BioSciences by 800.0% during the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock worth $51,000 after purchasing an additional 1,600 shares during the period. Finally, Natixis bought a new position in Pacira BioSciences during the first quarter valued at about $95,000. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.